BioWorld MedTech

Nov. 16, 2011

MASPP physician touts St. Jude's Epiducer system as 'pretty cool'

It's hard to miss the enthusiasm Frank Falco, MD, has for the new Epiducer lead delivery system from St. Jude Medical (St. Paul, Minnesota) when he talks about the unprecedented access the technology provides to the epidural space. Read More

NewCo on the Block: Bluegrass Vascular focuses on Surfacer 'inside out' catheter

Report from Europe: Neovasc receives CE mark for Reducer angina treatment

Washington roundup: House, Senate call for $50M boost in FDA's 2012 funding

Deals roundup: Alcon to pay $1.5M plus royalty fees for Iridex GreenTip rights

Agreements/contracts: Volition to earn revenues for blood profiling technology

Financings roundup: Echo's shareholder commits to warrant exercise of $2M

HIT roundup: Happyneuron offers MemTrax online memory-screening test

Patent watch: Awarepoint wins four U.S. patents for mesh-based location algorithm

Med-Tech Notes: Vibra opens Texas hospital

Product Briefs

People in the News

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...

Genescience presents STAT6 degrader for atopic dermatitis

BioWorld Science

Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....

Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis

BioWorld Science

Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...